Scientists at Biomerieux and the University of Lyon are collaborating on research to advance the discovery of biomarkers that can be used to diagnose or monitor disease.
The researchers are using next-generation, mass spectrometry technology with integrated triple quadrupoles and a linear accelerator trap to validate newly identified candidate biomarkers.
To accomplish these goals, they are using Applied Biosystems' (AB) Sciex Qtrap 5500 systems that rapidly quantify dozens of protein and peptide biomarkers in a single analysis.
The AB Sciex Qtrap 5500 system, which was developed by the Applied Biosystems/MDS Analytical Technologies joint venture, offers high reproducibility and precision and provides fast results.
The AB Sciex Qtrap 5500 systems are being used to develop simple, robust assays for detecting biomarkers that could then be transferred into standard testing procedures in diagnostic laboratories.
Biomarkers are indicators of the presence or progression of a disease that offer a quick and easy method for diagnosing or monitoring patients for a range of conditions, including cancers as well as infectious and degenerative diseases.
Extensive research is required to clarify the exact role and significance of each newly discovered candidate biomarker, which is a process that can take several years to complete.
The scientists from Biomerieux and the Institute of Analytical Sciences at the University of Lyon are combining their respective expertise in biomarker discovery and protein mass spectrometry to accelerate this biomarker validation process.
